DaVita Inc. 3rd Quarter 2025 Results

DENVER, Oct. 29, 2025 /PRNewswire/ -- DaVita Inc. (NYSE: DVA) announced financial and operating results for the quarter ended September 30, 2025.

"Our third quarter performance was in line with our expectations and keeps us on track to achieve our full-year guidance," said Javier Rodriguez, CEO of DaVita. "Our consistent focus on providing outstanding care is the key to these results, enabling us to continuously invest in improving the lives of our patients and supporting our dedicated teammates and physician partners."

Financial and operating highlights for the quarter ended September 30, 2025:

Three months ended

Nine months ended September 30,

September 30, 2025

June 30, 2025

2025

2024

Net income attributable to DaVita Inc.:

(dollars in millions, except per share data)

Net income

$ 150

$ 199

$ 513

$ 677

Diluted per share

$ 2.04

$ 2.58

$ 6.62

$ 7.66

Adjusted net income (1)

$ 185

$ 228

$ 576

$ 657

Adjusted diluted per share (1)

$ 2.51

$ 2.95

$ 7.44

$ 7.43

(1)

For definitions of non-GAAP financial measures, see the note titled "Note on Non-GAAP Financial Measures" and related reconciliations beginning on page 15.

Three months ended

Nine months ended September 30,

September 30, 2025

June 30, 2025

2025

2024

Amount

Margin

Amount

Margin

Amount

Margin

Amount

Margin

Operating income

(dollars in millions)

Operating income

$ 506

14.8 %

$ 538

15.9 %

$ 1,483

14.8 %

$ 1,525

16.0 %

Adjusted operating income (1)

$ 517

15.1 %

$ 551

16.3 %

$ 1,508

15.0 %

$ 1,490

15.6 %

(1)

For definitions of non-GAAP financial measures, see the note titled "Note on Non-GAAP Financial Measures" and related reconciliations beginning on page 15.

U.S. dialysis metrics:

Volume: Total U.S. dialysis treatments for the third quarter of 2025 were 7,242,725, or an average of 91,680 treatments per day, representing a per day decrease of (0.5)% compared to the second quarter of 2025. Normalized non-acquired treatment growth in the third quarter of 2025 compared to the third quarter of 2024 was (0.6)%.

Three months ended

Quarter

change

Nine months ended

Year to date

change

September 30,

2025

June 30,

2025

September 30,

2025

September 30,

2024

(dollars in millions, except per treatment data)

Revenue per treatment

$ 410.59

$ 404.58

$ 6.01

$ 405.15

$ 389.79

$ 15.36

Patient care costs per treatment

$ 273.54

$ 268.36

$ 5.18

$ 271.23

$ 255.96

$ 15.27

General and administrative

$ 322

$ 312

$ 10

$ 917

$ 858

$ 59

Primary drivers of the changes in the table above were as follows:

Revenue : The quarter change was primarily driven by an increase in average reimbursement rates, and other normal fluctuations, as well as an increase in the volume of phosphate binders. These increases are partially offset by changes in payor mix. The year to date change was driven by the incorporation of phosphate binders into the ESRD Prospective Payment System bundle, Medicare base rate and other annual rate increases, as well as other normal fluctuations.

Patient care costs: The quarter change was primarily due to increased compensation expense, pharmaceutical costs, principally related to volume of phosphate binders, and health benefit expense, partially offset by decreases in insurance costs. The year to date change was primarily driven by increases in pharmaceutical costs, principally due to the administration of phosphate binders, compensation expenses, and medical supplies expense.

General and administrative: The quarter change was primarily due to IT-related costs. The year to date change was primarily driven by increases in IT-related costs and costs related to the cybersecurity incident, as described below, as well as increases in compensation expense, partially offset by decreased center closure costs.

Certain items impacting the quarter:

Cybersecurity incident-related charges. During the second quarter of 2025, we experienced a cybersecurity incident that impacted certain elements of our network, and resulted in a temporary disruption of our operations. As a result of our efforts to remediate the incident and restore systems with the assistance of third-party cybersecurity professionals, we incurred general and administrative charges of approximately $11.7 million during the third quarter of 2025. During the nine months ended September 30, 2025, we incurred patient care costs of approximately $1.0 million and general and administrative expenses of approximately $24.2 million. These costs are excluded from our adjusted non-GAAP metrics and do not include the impact related to business interruption on our results.

Debt transaction. In July 2025, we entered into the Seventh Amendment to our senior secured credit agreement to refinance our existing Term Loan B-1 facility maturing May 9, 2031 with a repriced Term Loan B-2 facility in aggregate principal amount of $1.9 billion, which includes the incremental borrowing of Tranche B-2 term loans of $250 million. We used the proceeds from the new Term Loan B-2 facility to pay off the remaining principal balance outstanding and accrued interest and fees on our prior Term Loan B-1 in the amount of $1.6 billion and to repay a portion of the principal balance then outstanding on our Term Loan A-1 facility in the amount of $250 million.

Mozarc investment. During the third quarter of 2025, we incurred equity investment losses related to Mozarc Medical Holding LLC (Mozarc) of $51.3 million which included impairment and restructuring charges of $25.9 million. The impairment and restructuring charges are excluded from our adjusted non-GAAP metrics.

Share repurchases. During the three months ended September 30, 2025, we repurchased 3.3 million shares for $465 million, at an average price paid of $140.67 per share. Effective August 21, 2025, the Board increased the authorization under our existing share repurchase program by $2.0 billion in additional repurchasing authority.

Subsequent to September 30, 2025 through October 28, 2025, the Company has repurchased 0.4 million shares of our common stock for $54 million at an average price paid of $135.36 per share.

Financial and operating metrics:

Three months ended

September 30,

Twelve months ended

September 30,

2025

2024

2025

2024

Cash flow:

(dollars in millions)

Operating cash flow

$ 842

$ 810

$ 1,893

$ 1,960

Free cash flow (1)

$ 604

$ 555

$ 996

$ 1,139

(1)

For definitions of non-GAAP financial measures, see the note titled "Note on Non-GAAP Financial Measures" and related reconciliations beginning on page 15.

Three months ended

September 30, 2025

Nine months ended

September 30, 2025

Effective income tax rate on:

Income

22.2 %

22.4 %

Income attributable to DaVita Inc. (1)

31.3 %

29.6 %

Adjusted income attributable to DaVita Inc. (1)

27.9 %

26.1 %

(1)

For definitions of non-GAAP financial measures, see the note titled "Note on Non-GAAP Financial Measures" and related reconciliations beginning on page 15.

Center activity: As of September 30, 2025, we provided dialysis services to a total of approximately 293,200 patients at 3,247 outpatient dialysis centers, of which 2,662 centers were located in the United States and 585 centers were located in 14 countries outside of the United States. During the third quarter of 2025, we opened three and closed three dialysis centers in the United States, and acquired 58 and closed nine dialysis centers outside of the United States.

Integrated kidney care (IKC): As of September 30, 2025, we had approximately 64,900 patients in risk-based integrated care arrangements representing approximately $5.5 billion in annualized medical spend. We also had an additional 9,400 patients in other integrated care arrangements; we do not include the medical spend for these patients in this annualized medical spend estimate. For an additional description of these metrics, see footnote 6 in the "Supplemental Financial Data" table below.

Outlook:

The following forward-looking measures and the underlying assumptions involve significant known and unknown risks and uncertainties, including those described below, and actual results may vary materially from these forward-looking measures. We do not provide guidance for operating income or diluted net income per share attributable to DaVita Inc. on a basis consistent with United States generally accepted accounting principles (GAAP) nor a reconciliation of forward-looking non-GAAP financial measures to the most directly comparable GAAP financial measures on a forward-looking basis because we are unable to predict certain items contained in the GAAP measures without unreasonable efforts. These current non-GAAP financial measures do not include certain items, including cybersecurity costs, impairments included in equity losses and foreign currency fluctuations, which may be significant. The guidance for our effective income tax rate on adjusted income attributable to DaVita Inc. also excludes the amount of third-party owners' income and related taxes attributable to non-tax paying entities.

Current 2025 guidance

Prior 2025 guidance

Low

High

Low

High

(dollars in millions, except per share data)

Adjusted operating income

$2,035

$2,135

$2,010

$2,160

Adjusted diluted net income per share attributable to DaVita Inc.

$10.35

$11.15

$10.20

$11.30

Free cash flow

$1,000

$1,250

$1,000

$1,250

We will be holding a conference call to discuss our results for the third quarter ended September 30, 2025, on October 29, 2025, at 5:00 p.m. Eastern Time. To join the conference call, please dial (877) 918-6630 from the U.S. or (517) 308-9042 from outside the U.S., and provide the operator the password "Earnings." This call is being webcast and can be accessed at the DaVita Investor Relations website investors.davita.com. A replay of the conference call will also be available at investors.davita.com.

Forward looking statements

DaVita Inc. and its representatives may from time to time make written and oral forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA), including statements in this release, filings with the Securities and Exchange Commission (SEC), reports to stockholders and in meetings with investors and analysts. All statements in this release, during the related presentation or other meetings, other than statements of historical fact, are forward-looking statements and as such are intended to be covered by the safe harbor for "forward-looking statements" provided by the PSLRA. These forward-looking statements could include, among other things, statements about our balance sheet and liquidity, our expenses, revenues, billings and collections, patient census, the impact of the cybersecurity incident experienced by the Company in 2025, the potential impact of the federal government shutdown and the One Big Beautiful Bill Act (OBBBA) on our business, including with respect to federal funding of Medicaid and other government programs, availability or cost of supplies, including without limitation the impact of evolving trade policies and tariffs and any reduction in clinical and other supplies due to any disruptions experienced by third party vendors, including with respect to our ability to provide home dialysis services, treatment volumes, mix expectation, such as the percentage or number of patients under commercial insurance, including potential impacts to such mix as a result of the federal government shutdown or U.S. administration policies, current macroeconomic, marketplace and labor market conditions, and overall impact on our patients and teammates, as well as other statements regarding our future operations, financial condition and prospects, capital allocation plans, expenses, cost saving initiatives, other strategic initiatives, use of contract labor, government and commercial payment rates, expectations related to value-based care (VBC), integrated kidney care (IKC), Medicare Advantage (MA) plan enrollment and our international operations, expectations regarding increased competition and marketplace changes, including those related to new or potential entrants in the dialysis and pre-dialysis marketplace and the potential impact of innovative technologies, drugs, or other treatments on the dialysis industry, and expectations regarding our share repurchase program. All statements in this release, other than statements of historical fact, are forward-looking statements. Without limiting the foregoing, statements including the words "expect," "intend," "will," "could," "plan," "anticipate," "believe," "forecast," "guidance," "outlook," "goals," and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based on DaVita's current expectations and are based solely on information available as of the date of this release. DaVita undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of changed circumstances, new information, future events or otherwise, except as may be required by law. Actual future events and results could differ materially from any forward-looking statements due to numerous factors that involve substantial known and unknown risks and uncertainties. These risks and uncertainties include, among other things:

The financial information presented in this release is unaudited and is subject to change as a result of subsequent events or adjustments, if any, arising prior to the filing of the Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2025.

DAVITA INC.

CONSOLIDATED STATEMENTS OF INCOME

(unaudited)

(dollars and shares in thousands, except per share data)

Three months ended September 30,

Nine months ended September 30,

2025

2024

2025

2024

Dialysis patient service revenues

$ 3,298,090

$ 3,138,561

$ 9,607,954

$ 9,141,195

Other revenues

122,137

125,029

415,328

379,672

Total revenues

3,420,227

3,263,590

10,023,282

9,520,867

Operating expenses:

Patient care costs

2,332,759

2,151,875

6,833,959

6,373,150

General and administrative

414,373

393,534

1,201,268

1,123,859

Depreciation and amortization

177,490

187,014

528,645

549,758

Equity investment income, net

(10,162)

(3,711)

(23,135)

(15,874)

Gain on changes in ownership interests

—

(35,147)

Total operating expenses

2,914,460

2,728,712

8,540,737

7,995,746

Operating income

505,767

534,878

1,482,545

1,525,121

Debt expense

(150,557)

(134,583)

(431,674)

(331,748)

Debt extinguishment and modification costs

(5,150)

(10,081)

(5,150)

(19,813)

Other loss, net

(41,257)

(16,780)

(81,657)

(56,900)

Income before income taxes

308,803

373,434

964,064

1,116,660

Income tax expense

68,554

77,674

216,379

215,168

Net income

240,249

295,760

747,685

901,492

Less: Net income attributable to noncontrolling interests

(89,917)

(81,072)

(235,099)

(224,479)

Net income attributable to DaVita Inc.

$ 150,332

$ 214,688

$ 512,586

$ 677,013

Earnings per share attributable to DaVita Inc.:

Basic net income

$ 2.09

$ 2.56

$ 6.77

$ 7.86

Diluted net income

$ 2.04

$ 2.50

$ 6.62

$ 7.66

Weighted average shares for earnings per share:

Basic shares

72,075

83,721

75,768

86,123

Diluted shares

73,769

85,795

77,442

88,422

DAVITA INC.

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

(unaudited)

(dollars in thousands)

Three months ended September 30,

Nine months ended September 30,

2025

2024

2025

2024

Net income

$ 240,249

$ 295,760

$ 747,685

$ 901,492

Other comprehensive income (loss), net of tax:

Unrealized (losses) gains on interest rate cap agreements:

Unrealized losses

(4,418)

(21,576)

(19,358)

(2,340)

Reclassifications of net realized losses (gains) into net income

1,427

(1,870)

4,468

(45,539)

Unrealized gains (losses) on foreign currency translation

24,669

56,202

209,526

(62,371)

Other comprehensive income (loss)

21,678

32,756

194,636

(110,250)

Total comprehensive income

261,927

328,516

942,321

791,242

Less: Comprehensive income attributable to noncontrolling interests

(89,917)

(81,072)

(235,099)

(224,479)

Comprehensive income attributable to DaVita Inc.

$ 172,010

$ 247,444

$ 707,222

$ 566,763

DAVITA INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS

(unaudited)

(dollars in thousands)

Nine months ended September 30,

2025

2024

Cash flows from operating activities:

Net income

$ 747,685

$ 901,492

Adjustments to reconcile net income to net cash provided by operating activities:

Depreciation and amortization

528,645

549,758

Loss on extinguishment of debt

4,253

12,527

Stock-based compensation expense

101,559

75,392

Deferred income taxes

68,989

(53,713)

Equity investment loss, net

91,532

91,100

Gain on changes in ownership interests

—

(35,147)

Other non-cash losses

11,522

24,159

Changes in operating assets and liabilities, net of effect of acquisitions and divestitures:

Accounts receivable

(144,688)

(175,643)

Inventories

913

20,495

Other current assets

(153,428)

72,477

Other long-term assets

(21)

(12,858)

Accounts payable

97,879

(43,414)

Accrued compensation and benefits

19,279

27,314

Other current liabilities

16,462

35,646

Income taxes

(30,635)

(7,528)

Other long-term liabilities

(14,172)

(7,646)

Net cash provided by operating activities

1,345,774

1,474,411

Cash flows from investing activities:

Additions of property and equipment

(430,434)

(384,786)

Acquisitions

(118,337)

(161,210)

Proceeds from asset and business sales

32,337

17,937

Purchase of debt investments held-to-maturity

(15,842)

(15,319)

Purchase of other debt and equity investments

(3,352)

(8,784)

Proceeds from debt investments held-to-maturity

38,051

22,092

Proceeds from sale of other debt and equity investments

6,706

4,558

Purchase of equity method investments

(2,466)

(4,497)

Distributions from equity method investments

1,514

6,554

Net cash used in investing activities

(491,823)

(523,455)

Cash flows from financing activities:

Borrowings

4,672,170

6,623,634

Payments on long-term debt

(3,880,721)

(5,437,907)

Deferred and debt related financing costs

(26,416)

(46,011)

Purchase of treasury stock from related party

(430,286)

—

Other purchases of treasury stock

(1,033,887)

(1,020,550)

Distributions to noncontrolling interests

(232,721)

(229,236)

Net proceeds from issuance of common stock under employee stock plans

17,583

15,204

Payment of tax withholdings on net share settlements of equity awards

(33,764)

(127,700)

Contributions from noncontrolling interests

3,999

10,623

Proceeds from sales of additional noncontrolling interests

169

860

Purchases of noncontrolling interests

(16,385)

(40,751)

Net cash used in financing activities

(960,259)

(251,834)

Effect of exchange rate changes on cash, cash equivalents and restricted cash

21,897

(5,112)

Net (decrease) increase in cash, cash equivalents and restricted cash

(84,411)

694,010

Cash, cash equivalents and restricted cash at beginning of the year

879,825

464,634

Cash, cash equivalents and restricted cash at end of the period

$ 795,414

$ 1,158,644

DAVITA INC.

CONSOLIDATED BALANCE SHEETS

(unaudited)

(dollars and shares in thousands, except per share data)

September 30, 2025

December 31, 2024

ASSETS

Cash and cash equivalents

$ 705,960

$ 794,933

Restricted cash and equivalents

89,454

84,892

Short-term investments

30,524

51,064

Accounts receivable

2,333,319

2,146,975

Inventories

139,092

134,559

Other receivables

521,863

383,166

Prepaid and other current assets

160,968

122,948

Income tax receivable

130,646

27,535

Total current assets

4,111,826

3,746,072

Property and equipment, net of accumulated depreciation of $6,653,987 and $6,262,703, respectively

2,853,343

2,940,916

Operating lease right-of-use assets

2,323,123

2,393,558

Intangible assets, net of accumulated amortization of $34,444 and $32,408, respectively

219,673

197,431

Equity method and other investments

259,436

336,684

Long-term investments

40,134

33,660

Other long-term assets

204,479

261,731

Goodwill

7,543,878

7,375,216

$ 17,555,892

$ 17,285,268

LIABILITIES AND EQUITY

Accounts payable

$ 655,598

$ 547,200

Other liabilities

933,985

934,145

Accrued compensation and benefits

851,852

800,484

Current portion of operating lease liabilities

432,015

410,411

Current portion of long-term debt

62,921

270,867

Income tax payable

26,410

10,303

Due to related party

54,347

—

Total current liabilities

3,017,128

2,973,410

Long-term operating lease liabilities

2,099,531

2,209,655

Long-term debt

10,183,863

9,175,903

Other long-term liabilities

172,195

169,588

Deferred income taxes

742,453

665,361

Total liabilities

16,215,170

15,193,917

Commitments and contingencies

Noncontrolling interests subject to put provisions

1,644,954

1,695,483

Equity:

Preferred stock ($0.001 par value, 5,000 shares authorized; none issued)

—

Common stock ($0.001 par value, 450,000 shares authorized; 90,811 and 70,977 shares issued

and outstanding at September 30, 2025, respectively, 90,369 and 80,536 shares issued and

outstanding at December 31, 2024, respectively)

Additional paid-in capital

401,785

286,270

Retained earnings

2,047,216

1,534,630

Treasury stock (19,834 and 9,833 shares, respectively)

(2,904,806)

(1,389,072)

Accumulated other comprehensive loss

(116,160)

(310,796)

Total DaVita Inc. shareholders' equity (deficit)

(571,874)

121,122

Noncontrolling interests not subject to put provisions

267,642

274,746

Total equity (deficit)

(304,232)

395,868

$ 17,555,892

$ 17,285,268

DAVITA INC.

SUPPLEMENTAL FINANCIAL DATA

(unaudited)

(dollars in millions and shares in thousands, except per treatment and patient data)

Three months ended

Nine months ended

September 30, 2025

September 30,

2025

June 30,

2025

1. Consolidated business metrics:

Operating margin

14.8 %

15.9 %

14.8 %

Adjusted operating margin excluding certain items (2)

15.1 %

16.3 %

15.0 %

General and administrative expenses as a percent of consolidated revenues (1)

12.1 %

12.2 %

12.0 %

Effective income tax rate on income

22.2 %

25.4 %

22.4 %

Effective income tax rate on income attributable to DaVita Inc. (2)

31.3 %

31.9 %

29.6 %

Effective income tax rate on adjusted income attributable to DaVita Inc. (2)

27.9 %

25.5 %

26.1 %

2. Summary of financial results:

Revenues:

U.S. dialysis patient services and other

$ 2,980

$ 2,913

$ 8,717

Other—Ancillary services

Integrated kidney care

152

352

Other U.S. ancillary

International dialysis patient service and other

352

325

979

455

486

1,355

Eliminations

(15)

(20)

(49)

Total consolidated revenues

$ 3,420

$ 3,380

$ 10,023

Operating income (loss):

U.S. dialysis

$ 530

$ 523

$ 1,529

Other—Ancillary services

Integrated kidney care

(21)

(24)

Other U.S. ancillary

(4)

(5)

(14)

International

Corporate administrative support expenses

(26)

(42)

(101)

Total consolidated operating income

$ 506

$ 538

$ 1,483

DAVITA INC.

SUPPLEMENTAL FINANCIAL DATA - continued

(unaudited)

(dollars in millions and shares in thousands, except per treatment and patient data)

Three months ended

Nine months ended

September 30, 2025

September 30,

2025

June 30,

2025

3. Summary of reportable segment financial results and metrics:

U.S. dialysis

Financial results

Revenue:

Dialysis patient service revenues

$ 2,974

$ 2,907

$ 8,698

Other revenues

Total operating revenues

2,980

2,913

8,717

Operating expenses:

Patient care costs

1,981

1,928

5,823

General and administrative

322

312

917

Depreciation and amortization

156

157

470

Equity investment income

(10)

(7)

(22)

Total operating expenses

2,450

2,391

7,188

Segment operating income

$ 530

$ 523

$ 1,529

Reconciliation for non-GAAP measure:

Cybersecurity incident-related charges

Adjusted segment operating income (2)

$ 542

$ 536

$ 1,554

Metrics

Volume:

Treatments

7,242,725

7,186,217

21,469,460

Number of treatment days

79.0

78.0

233.7

Average treatments per day

91,680

92,131

91,868

Per day year-over-year change

(1.5) %

(1.1) %

(1.0) %

Normalized year-over-year non-acquired treatment growth (3)

(0.6) %

(0.8) %

Operating net revenues:

Average patient service revenue per treatment

$ 410.59

$ 404.58

$ 405.15

Expenses:

Patient care costs per treatment

$ 273.54

$ 268.36

$ 271.23

General and administrative expenses per treatment

$ 44.51

$ 43.43

$ 42.72

Depreciation and amortization expense per treatment

$ 21.57

$ 21.82

$ 21.89

Accounts receivable:

Receivables

$ 1,704

$ 1,838

DSO

4. IKC metrics:

Patients per integrated care arrangement type:

Risk-based (6)

64,900

64,400

Other (6)

9,400

9,300

Annualized aggregate risk based spend (6)

$ 5,500

$ 5,300

DAVITA INC.

SUPPLEMENTAL FINANCIAL DATA - continued

(unaudited)

(dollars in millions and shares in thousands, except per treatment and patient data)

Three months ended

Nine months ended

September 30, 2025

September 30,

2025

June 30,

2025

5. Cash flow:

Operating cash flow

$ 842

$ 324

$ 1,346

Operating cash flow, last twelve months

$ 1,893

$ 1,862

Free cash flow (2)

$ 604

$ 157

$ 716

Free cash flow, last twelve months (2)

$ 996

$ 947

Capital expenditures:

Maintenance

$ 119

$ 90

$ 304

Development

$ 47

$ 32

$ 126

Acquisition expenditures

$ 108

$ —

$ 118

Proceeds from sale of self-developed properties

$ 8

$ 12

$ 29

6. Debt and capital structure:

Total debt (4)

$ 10,310

$ 10,330

Net debt, net of cash and cash equivalents (4)

$ 9,604

$ 9,622

Leverage ratio (5)

3.37x

3.34x

Weighted average effective interest rate:

During the quarter

5.70 %

5.71 %

At end of the quarter

5.70 %

5.73 %

On the senior secured credit facilities at end of the quarter

6.51 %

6.60 %

Debt with fixed and capped rates as a percentage of total debt:

Debt with rates fixed by its terms

63 %

Debt with rates fixed by its terms or capped by cap agreements

97 %

Amount spent on share repurchases

$ 465

$ 446

$ 1,461

Number of shares repurchased

3,274

3,067

10,001

Certain columns, rows or percentages may not sum or recalculate due to the presentation of rounded numbers.

(1)

General and administrative expenses include certain corporate support, long-term incentive compensation and advocacy costs.

(2)

These are non-GAAP financial measures. For a reconciliation of these non-GAAP financial measures to their most comparable measure calculated and presented in accordance with GAAP, and for a definition of adjusted amounts, see attached reconciliation schedules. Adjusted operating income margin is adjusted operating income divided by consolidated revenues.

(3)

Normalized non-acquired treatment growth reflects year-over-year growth in treatment volume, adjusted to exclude acquisitions and other similar transactions, and further adjusted to normalize for the number and mix of treatment days in a given quarter versus the prior year quarter.

(4)

The debt amounts as of September 30, 2025 and June 30, 2025 presented exclude approximately $62.8 and $69.2, respectively, of debt discount, premium and other deferred financing costs related to our senior secured credit facilities and senior notes in effect or outstanding at that time.

(5)

This is a non-GAAP measure. See "Calculation of Leverage Ratio" in non-GAAP reconciliations.

(6)

Integrated care metrics: The aggregate amount of medical spend associated with risk-based integrated care arrangements that we disclose includes both medical costs included in our reported expenses for certain risk-based arrangements (such as our SNPs), as well as the aggregate estimated benchmark amount above or below which we will incur profit or loss from value-based care (VBC) arrangements under which third-party medical costs are not included in our reported results. A number of our VBC contracts are subject to complex or novel patient attribution mechanics and benchmark adjustments, some of which are based on information not reported to us until periods after we report our quarterly results. As a result, our estimates of our patients under, and the dollar amount of, our value-based contracts remain subject to estimation uncertainty.

DAVITA INC.

RECONCILIATIONS FOR NON-GAAP MEASURES

(unaudited)

(dollars in millions)

Calculation of the Leverage Ratio

Under our amended senior secured credit facilities (the Amended Credit Agreement) dated July 17, 2025 and our prior senior secured credit facilities, the leverage ratio is defined as (a) all funded debt, minus unrestricted cash and cash equivalents (including short-term investments) not to exceed $750 divided by (b) "Consolidated EBITDA." The leverage ratio determines the interest rate margin payable by the Company for its Term Loan A-1 and revolving line of credit under the Amended Credit Agreement by establishing the margin over the base interest rate (SOFR plus credit spread adjustment) that is applicable. The calculation below is based on the last 12 months of "Consolidated EBITDA" and "Consolidated net debt" at the end of each reported period, each as defined in the Amended Credit Agreement. The calculation of "Consolidated EBITDA" below sets forth, among other things, certain pro forma adjustments described in the Amended Credit Agreement, including pro forma adjustments for acquisitions or divestitures that occurred during the period and certain projected net cost savings, expense reductions and cost synergies. These pro forma adjustments are determined according to specified criteria set forth in the Amended Credit Agreement, and as a result, the total adjustments calculated may not be comparable to the Company's estimates for other purposes, including as operating performance measures. The Company's management believes the presentation of "Consolidated EBITDA" is useful to investors to enhance their understanding of the Company's leverage ratio under the Amended Credit Agreement and should not be evaluated for any other purpose. The leverage ratio calculated by the Company is a non-GAAP measure and should not be considered a substitute for the ratio of total debt to operating income, determined in accordance with GAAP. The Company's calculation of its leverage ratio might not be calculated in the same manner as, and thus might not be comparable to, similarly titled measures of other companies.

Twelve months ended

September 30,

2025

June 30,

2025

Net income attributable to DaVita Inc.

$ 772

$ 836

Income taxes

281

290

Interest expense

501

481

Depreciation and amortization

703

712

Net income attributable to noncontrolling interests

325

316

Stock-settled stock-based compensation

128

114

Debt extinguishment and modification costs

Gain on changes in ownership interests

(74)

Expected cost savings and expense reductions

Other

191

181

"Consolidated EBITDA"

$ 2,844

$ 2,871

September 30,

2025

June 30,

2025

Total debt, excluding debt discount and other deferred financing costs (1)

$ 10,310

$ 10,330

Less: Cash and cash equivalents including short-term investments (2)

(732)

(737)

Consolidated net debt

$ 9,577

$ 9,594

Last twelve months "Consolidated EBITDA"

$ 2,844

$ 2,871

Leverage ratio

3.37x

3.34x

Maximum leverage ratio permitted under the Credit Agreement

5.00x

Certain columns or rows may not sum or recalculate due to the presentation of rounded numbers.

(1)

(2)

This excludes amounts not readily convertible to cash related to the Company's non-qualified deferred compensation plans for all periods presented. The Amended Credit Agreement limits the amount deducted for cash and cash equivalents, including short-term investments, to the lesser of all unrestricted cash and cash equivalents, including short-term investments of the Company or $750.

DAVITA INC.

RECONCILIATIONS FOR NON-GAAP MEASURES

(unaudited)

Note on Non-GAAP Financial Measures

As used in this press release, the term "adjusted" refers to non-GAAP measures as follows, each as reconciled to its most comparable GAAP measure as presented in the non-GAAP reconciliations in the notes to this press release: (i) for income and expense measures, the term "adjusted" refers to operating performance measures that exclude certain items such as, but not limited to, cybersecurity costs, impairment charges, (gain) loss on ownership changes, restructuring charges, accruals for legal matters, and debt extinguishment and modification costs; and (ii) the term "effective income tax rate on adjusted income attributable to DaVita Inc." represents the Company's effective tax rate excluding applicable non-GAAP items and the tax associated with them as well as noncontrolling owners' income, which primarily relates to non-tax paying entities.

These non-GAAP or "adjusted" measures are presented because management believes these measures are useful adjuncts to GAAP results. However, these non-GAAP measures should not be considered alternatives to the corresponding measures determined under GAAP.

Specifically, management uses adjusted operating income, adjusted net income attributable to DaVita Inc. and adjusted diluted net income per share attributable to DaVita Inc. to compare and evaluate our performance period over period and relative to competitors, to analyze the underlying trends in our business, to establish operational budgets and forecasts and for incentive compensation purposes. We believe these non-GAAP measures also are useful to investors and analysts in evaluating our performance over time and relative to competitors, as well as in analyzing the underlying trends in our business. Furthermore, we believe these presentations enhance a user's understanding of our normal consolidated results by excluding certain items which we do not believe are indicative of our ordinary results of operations. As a result, adjusting for these amounts allows for comparison to our normalized prior period results.

The effective income tax rate on adjusted income attributable to DaVita Inc. excludes noncontrolling owners' income and certain non-deductible and other charges which we do not believe are indicative of our ordinary results. Accordingly, we believe these adjusted effective income tax rates are useful to management, investors and analysts in evaluating our performance and establishing expectations for income taxes incurred on our ordinary results attributable to DaVita Inc.

Finally, free cash flow represents net cash provided by operating activities less distributions to noncontrolling interests, development capital expenditures, and maintenance capital expenditures; plus contributions from noncontrolling interests and proceeds from the sale of self-developed properties. Management uses this measure to assess our ability to fund acquisitions and meet our debt service obligations and we believe this measure is equally useful to investors and analysts as an adjunct to cash flows from operating activities and other measures under GAAP.

It is important to bear in mind that these non-GAAP "adjusted" measures are not measures of financial performance or liquidity under GAAP and should not be considered in isolation from, nor as substitutes for, their most comparable GAAP measures.

The following reconciliations of the non-GAAP financial measures presented in this press release to their most comparable GAAP measures.

DAVITA INC.

RECONCILIATIONS FOR NON-GAAP MEASURES - continued

(unaudited)

(dollars in millions, except per share data)

Adjusted net income and adjusted diluted net income per share attributable to DaVita Inc.:

Three months ended

Nine months ended

September 30,

2025

June 30,

2025

September 30,

2025

September 30,

2024

Dollars

Per share

Dollars

Per share

Dollars

Per share

Dollars

Per share

Consolidated:

Net income attributable to DaVita Inc.

$ 150

$ 2.04

$ 199

$ 2.58

$ 513

$ 6.62

$ 677

$ 7.66

Cybersecurity incident-related charges (1)

0.16

0.17

0.33

—

Gain on changes in ownership interests (2)

—

(35)

(0.40)

Other loss, net - Mozarc loss (3)

0.35

—

0.33

—

Debt refinancing charges (4)

—

0.22

Income tax impact related to prior legal

matter (5)

—

0.24

—

Related income tax

(3)

(0.04)

(3)

(0.04)

(6)

(0.08)

(5)

(0.06)

Adjusted net income attributable to DaVita Inc.

$ 185

$ 2.51

$ 228

$ 2.95

$ 576

$ 7.44

$ 657

$ 7.43

Certain columns, rows or percentages may not sum or recalculate due to the presentation of rounded numbers.

Adjusted operating income:

Three months ended September 30, 2025

U.S.

dialysis

Ancillary services

Corporate

administration

U.S. IKC

U.S. Other

International

Total

Consolidated

Operating income (loss)

$ 530

$ (21)

$ (4)

$ 27

$ 1

$ (26)

$ 506

Cybersecurity incident-related charges (1)

—

Adjusted operating income (loss)

$ 542

$ (21)

$ (4)

$ 27

$ 1

$ (26)

$ 517

Certain columns or rows may not sum or recalculate due to the presentation of rounded numbers.

Three months ended June 30, 2025

U.S.

dialysis

Ancillary services

Corporate

administration

U.S. IKC

U.S. Other

International

Total

Consolidated

Operating income (loss)

$ 523

$ 26

$ (5)

$ 36

$ 57

$ (42)

$ 538

Cybersecurity incident-related charges (1)

—

Adjusted operating income (loss)

$ 536

$ 26

$ (5)

$ 36

$ 57

$ (42)

$ 551

Certain columns or rows may not sum or recalculate due to the presentation of rounded numbers.

Nine months ended September 30, 2025

U.S.

dialysis

Ancillary services

Corporate

administration

Consolidated

U.S. IKC

U.S. Other

International

Total

Operating income (loss)

$ 1,529

$ (24)

$ (14)

$ 93

$ 55

$ (101)

$ 1,483

Cybersecurity incident-related charges (1)

—

Adjusted operating income (loss)

$ 1,554

$ (24)

$ (14)

$ 93

$ 55

$ (101)

$ 1,508

Certain columns or rows may not sum or recalculate due to the presentation of rounded numbers.

DAVITA INC.

RECONCILIATIONS FOR NON-GAAP MEASURES - continued

(unaudited)

(dollars in millions, except per share data)

Nine months ended September 30, 2024

U.S.

dialysis

Ancillary services

Corporate

administration

Consolidated

U.S. IKC

U.S. Other

International

Total

Operating income (loss)

$ 1,625

$ (48)

$ (19)

$ 51

$ (16)

$ (84)

$ 1,525

Gain on changes in ownership interests (2)

(35)

—

(35)

Adjusted operating income (loss)

$ 1,590

$ (48)

$ (19)

$ 51

$ (16)

$ (84)

$ 1,490

Certain columns or rows may not sum or recalculate due to the presentation of rounded numbers.

Effective income tax rates:

Three months ended

Nine months

ended

September 30,

2025

September 30,

2025

June 30,

2025

Effective income tax rates on income attributable to DaVita Inc.:

Income before income taxes

$ 309

$ 369

$ 964

Noncontrolling owners' income primarily attributable to non-tax paying entities

(90)

(76)

(236)

Income before income taxes attributable to DaVita Inc.

$ 219

$ 293

$ 729

Income tax expense

$ 69

$ 94

$ 216

Taxes attributable to noncontrolling interests

—

Income tax expense attributable to DaVita Inc.

$ 68

$ 93

$ 216

Effective income tax rate on income attributable to DaVita Inc.

31.3 %

31.9 %

29.6 %

Effective income tax rate on adjusted income attributable to DaVita Inc.:

Income before income taxes

$ 309

$ 369

$ 964

Cybersecurity incident-related charges (1)

Other loss, net - Mozarc loss (3)

—

Noncontrolling owners' income primarily attributable to non-tax paying entities

(90)

(76)

(236)

Adjusted income before income taxes attributable to DaVita Inc.

$ 256

$ 306

$ 780

Income tax expense

$ 69

$ 94

$ 216

Plus income tax related to:

Cybersecurity incident-related charges (1)

Less income tax related to:

Income tax impact related to prior legal matter (5)

—

(19)

Taxes attributable to noncontrolling interests

—

Income tax on adjusted income attributable to DaVita Inc.

$ 71

$ 78

$ 203

Effective income tax rate on adjusted income attributable to DaVita Inc.

27.9 %

25.5 %

26.1 %

Certain columns, rows or percentages may not sum or recalculate due to the presentation of rounded numbers.

DAVITA INC.

RECONCILIATIONS FOR NON-GAAP MEASURES - continued

(unaudited)

(dollars in millions, except per share data)

Free cash flow:

Three months ended

Nine months

ended

September 30,

2025

September 30,

2025

June 30,

2025

September 30,

2024

Net cash provided by operating activities

$ 842

$ 324

$ 810

$ 1,346

Adjustments to reconcile net cash provided by operating activities to

free cash flow:

Distributions to noncontrolling interests

(82)

(58)

(122)

(233)

Contributions from noncontrolling interests

—

Maintenance capital expenditures (6)

(119)

(90)

(104)

(304)

Development capital expenditures (7)

(47)

(32)

(35)

(126)

Proceeds from sale of self-developed properties

Free cash flow

$ 604

$ 157

$ 555

$ 716

Certain columns or rows may not sum or recalculate due to the presentation of rounded numbers.

Twelve months ended

September 30,

2025

June 30,

2025

September 30,

2024

Net cash provided by operating activities

$ 1,893

$ 1,862

$ 1,960

Adjustments to reconcile net cash provided by operating activities to free cash flow:

Distributions to noncontrolling interests

(341)

(381)

(307)

Contributions from noncontrolling interests

Maintenance capital expenditures (6)

(423)

(407)

(394)

Development capital expenditures (7)

(178)

(167)

(150)

Proceeds from sale of self-developed properties

Free cash flow

$ 996

$ 947

$ 1,139

Certain columns or rows may not sum or recalculate due to the presentation of rounded numbers.

(1)

Represents charges recognized to work to remediate a cybersecurity incident and restore systems following the occurrence of the incident in the second quarter of 2025. We have excluded these charges from our non-GAAP metrics as we do not believe they are indicative of our ordinary results of operations.

(2)

Represents a non-cash gain recognized on the acquisition of a controlling financial interest in a previously nonconsolidated dialysis partnership. This gain to mark our prior investment in the business to fair value before consolidation does not represent a normal and recurring requirement of operating our business or generating revenues and may obscure analysis of underlying trends and financial performance.

(3)

Represents non-cash impairment and restructuring charges included in other losses related to our equity investment in Mozarc Medical Holding LLC (Mozarc). This loss does not represent a normal and recurring cost of operating our business or generating returns from investments and may obscure analysis of underlying trends and financial performance.

(4)

Represents the non-cash write-off of deferred financing costs and cash charges for creditor fees and third-party costs associated with the Company's senior secured credit agreement. Costs associated with refinancing the Company's debt are not indicative of normal debt expense and may obscure analysis of underlying trends and financial performance.

(5)

Represents the write-down of a tax receivable related to a 2014 tax refund claim. The claim related to estimated tax expense associated with a legal matter previously presented as a non-GAAP adjustment. We have excluded this charge from our non-GAAP metrics because, among other things, we do not believe it is indicative of our ordinary results of operations because the charge is significant and may obscure analysis of underlying trends and financial performance of our current business.

(6)

Maintenance capital expenditures represent capital expenditures to maintain the productive capacity of the business and include those made for investments in information technology, dialysis center renovations, capital asset replacements, and any other capital expenditures that are not development or acquisition expenditures.

(7)

Development capital expenditures principally represent capital expenditures (other than acquisition expenditures) made to expand the productive capacity of the business and include those for new U.S. and international dialysis center developments, dialysis center expansions and relocations, and new or expanded contracted hospital operations.

Contact:

Investor Relations

DaVita Inc.

ir@davita.com

SOURCE DaVita